{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:49:38Z","timestamp":1787014178100,"version":"build-2736575974"},"reference-count":59,"publisher":"Wiley","issue":"S2","license":[{"start":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T00:00:00Z","timestamp":1535500800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100001454","name":"American Epilepsy Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001454","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    A subgroup of patients with drug\u2010resistant epilepsy have seizure clusters, which are a part of the continuum of seizure emergencies that includes prolonged episodes and status epilepticus. When the patient or caregiver can identify the beginning of a cluster, the condition is amenable to certain treatments, an approach known as rescue therapy. Intravenous drug administration offers the fastest onset of action, but this route is usually not an option because most seizure clusters occur outside of a medical facility. Alternate routes of administration have been used or are proposed including rectal, buccal, intrapulmonary, subcutaneous, intramuscular, and intranasal. The objective of this narrative review is to describe the (1) anatomical, physiologic, and drug physicochemical properties that need to be considered when developing therapies for seizure emergencies and (2) products currently in development. New therapies must consider parameters of Fick's law such as absorptive surface area, blood flow, membrane thickness, and lipid solubility, because these factors affect both rate and extend of absorption. For example, the lung has a 50\u00a0000\u2010fold greater absorptive surface area than that associated with a subcutaneous injection. Lipid solubility is a physicochemical property that influences the absorption rate of small molecule drugs. Among drugs currently used or under development for rescue therapy, allopregnanolone has the greatest lipid solubility at physiologic\n                    <jats:styled-content style=\"fixed-case\">pH<\/jats:styled-content>\n                    , followed by propofol, midazolam, diazepam, lorazepam, alprazolam, and brivaracetam. However, greater lipid solubility correlates with lower water solubility, complicating formulation of rescue therapies. One approach to overcoming poor aqueous solubility involves the use of a water\u2010soluble prodrug coadministered with a converting enzyme, which is being explored for the intranasal delivery of diazepam. With advances in seizure prediction technology and the development of drug delivery systems that provide rapid onset of effect, rescue therapies may prevent the occurrence of seizures, thus greatly improving the management of epilepsy.\n                  <\/jats:p>","DOI":"10.1111\/epi.14479","type":"journal-article","created":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T07:25:35Z","timestamp":1535613935000},"page":"207-215","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Rescue therapies for seizure emergencies: New modes of administration"],"prefix":"10.1111","volume":"59","author":[{"given":"Patricia D.","family":"Maglalang","sequence":"first","affiliation":[{"name":"Center for Orphan Drug Research University of Minnesota Minneapolis MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davin","family":"Rautiola","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics College of Pharmacy University of Minnesota Minneapolis MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald A.","family":"Siegel","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics College of Pharmacy University of Minnesota Minneapolis MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared M.","family":"Fine","sequence":"additional","affiliation":[{"name":"Neuroscience Research at HealthPartners Institute St. Paul MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah R.","family":"Hanson","sequence":"additional","affiliation":[{"name":"Neuroscience Research at HealthPartners Institute St. Paul MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa D.","family":"Coles","sequence":"additional","affiliation":[{"name":"Center for Orphan Drug Research University of Minnesota Minneapolis MN USA"},{"name":"Department of Experimental and Clinical Pharmacology College of Pharmacy University of Minnesota Minneapolis MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Cloyd","sequence":"additional","affiliation":[{"name":"Center for Orphan Drug Research University of Minnesota Minneapolis MN USA"},{"name":"Department of Experimental and Clinical Pharmacology College of Pharmacy University of Minnesota Minneapolis MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,8,29]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000177"},{"key":"e_1_2_9_3_1","unstructured":"SchachterSC ShaferPO SirvenJI.What is a seizure emergency 2013. Available at:http:\/\/www.epilepsy.com\/get-help\/managing-your-epilepsy\/understanding-seizures-and-emergencies\/what-seizure-emergency. Accessed April 1 2017."},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.5698\/1535-7597-16.1.48"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000000099"},{"key":"e_1_2_9_6_1","first-page":"618","volume-title":"Handbook of toxicology","author":"Abou\u2010Donia MB","year":"2014"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneng.2013.00007"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1462-5822.2006.00694.x"},{"key":"e_1_2_9_9_1","unstructured":"FreitasRAJr Nanomedicine volume I: basic capabilities. Landes bioscience. Texas: Georgetown 1999: Table\u00a08.4."},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2006.07.009"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01794949"},{"key":"e_1_2_9_12_1","volume-title":"Colon: structure and function","author":"Bustos\u2010Fern\u00e1ndez L","year":"2013"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2011.02.033"},{"key":"e_1_2_9_14_1","first-page":"491","article-title":"Characterising the variability in adult human nasal airway dimensions","volume":"41","author":"Guilmette R","year":"1997","journal-title":"Ann Occup Hyg"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0022215100106462"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/00220345870660080201"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-5173(98)00109-4"},{"key":"e_1_2_9_18_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-4899-7558-4","volume-title":"Oral mucosal drug delivery and therapy","author":"Rathbone M","year":"2015"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.3109\/08958370902767070"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600790304"},{"key":"e_1_2_9_21_1","first-page":"245","article-title":"Bioadhesion and biomimetics: from nature to applications","volume":"237","author":"Bianco\u2010Peled H","year":"2015","journal-title":"Pan Stanford"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.2174\/156720112803529828"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2016.07.001"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm020266b"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv951"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/36.1.62"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/109158180302200507"},{"key":"e_1_2_9_28_1","unstructured":"Hospira Inc.Midazolam CIV injection USP. Available at:http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=4529. Accessed May 22 2017."},{"key":"e_1_2_9_29_1","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0022-3565(25)22081-X","article-title":"In vitro correlates of benzodiazepine cerebrospinal fluid uptake, pharmacodynamic action and peripheral distribution","volume":"227","author":"Arendt RM","year":"1983","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/00912700122012779"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2010.10.001"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009358083"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2013.06.002"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781118799536"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.5b00146"},{"key":"e_1_2_9_36_1","first-page":"1","article-title":"Guidance for industry: nasal spray and inhalation solution, suspension, and spray drug products\u2014Chemistry, manufacturing, and controls documentation","volume":"1","author":"US Food and Drug Administration","year":"2002","journal-title":"Fed Regist"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1535-7597.2004.42001.x"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.etp.2008.01.013"},{"key":"e_1_2_9_39_1","unstructured":"Alexza Pharmaceuticals Inc. Staccato system: Alexza's Technology Foundation.2017. Available at:http:\/\/www.alexza.com\/staccato\/staccato-overview. Accessed March 30 2017."},{"key":"e_1_2_9_40_1","unstructured":"Personal communications with representativesfrom Alexza Pharmaceuticals Inc."},{"key":"e_1_2_9_41_1","first-page":"131","article-title":"Inhalation drug delivery devices: technology update","volume":"8","author":"Ibrahim M","year":"2015","journal-title":"Med Devices"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2016.05.029"},{"key":"e_1_2_9_43_1","volume-title":"Pharmaceutics: basic principles and application to pharmacy practice","author":"Dash A","year":"2013"},{"key":"e_1_2_9_44_1","unstructured":"Personal communications with representativesfrom Xeris Pharmaceuticals Inc."},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.321.7271.1237"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.49.9.1050"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107494"},{"key":"e_1_2_9_48_1","unstructured":"Personal communicationswith representatives from Pfizer."},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.316"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1998.tb01375.x"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-015-0271-x"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-3659(02)00363-2"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6446(02)02452-2"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13131"},{"key":"e_1_2_9_55_1","unstructured":"Proximagen Limited.Midazolam Nasal Spray (USL261) Phase 3 Trial Meets Primary Efficacy Endpoint In Patients With Seizure Clusters. PRNewswire (in press 2017)"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2013.02.018"},{"key":"e_1_2_9_57_1","unstructured":"Personal communicationswith representatives from Neurelis Inc."},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03611.x"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-014-9596-5"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2008.07.030"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fepi.14479","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/epi.14479","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T14:06:55Z","timestamp":1751810815000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/epi.14479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,29]]},"references-count":59,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.1111\/epi.14479"],"URL":"https:\/\/doi.org\/10.1111\/epi.14479","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,29]]},"assertion":[{"value":"2018-02-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}